|
|
Article: EOPHARM BEGINS NEW GLOBAL TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA.
- Article from:
- Worldwide Biotech
- Article date:
- October 1, 2002
CopyrightCOPYRIGHT 2002 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NeoPharm, Inc. (Nasdaq National Market: NEOL), Lake Forest, Ill., has announced further progress in its clinical development program for IL13-PE38, NeoPharm's novel tumor-targeted agent. Enrollment has begun in the first global Phase I/II clinical trial of IL13-PE38; the third clinical study to date in patients with recurrent or progressive malignant glioma. The trial is being conducted at six participating sites including University Hospital Eppendorf and University Hospital Kiel in Germany, Chaim Sheba Medical Center and Dana Hospital Tel Aviv in Israel, Cleveland Clinic and University of Colorado in the United States. The trial's first cohort of three patients was ...